Instil Bio
Yi Fang has a strong background in tax management, with a focus on senior roles. They began their career in 2008 as a Senior Tax Associate at PricewaterhouseCoopers before moving on to roles as a Senior Tax Analyst at Anritsu and VeriFone. In 2015, they transitioned to a Tax Manager position at Amgen and later became a Senior Tax Manager at both AECOM and Amgen. Most recently, Yi Fang worked as a Senior Tax Manager at Wish before assuming their current role as the Global Tax Director at Instil Bio in 2022.
Yi Fang attended the University of California, Berkeley from 2005 to 2007, where they obtained a Bachelor's degree in Economics, Applied Math, and Accounting. No additional certifications or institutions are provided.
This person is not in any offices
Instil Bio
1 followers
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.